Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Arctic Bioscience AS ( (DE:9TD) ).
Arctic Bioscience reported a strong finish to 2025 with fourth-quarter nutraceutical revenue of NOK 13.9 million and stable gross margins, despite full-year sales slipping to NOK 39.8 million after a 2024 product recall and related extraordinary costs. The company sharply reduced operational expenses, improving adjusted EBITDA to negative NOK 28.3 million from negative NOK 36.8 million, while boosting its credit facility and ending the year with NOK 5.2 million in liquidity.
Management highlighted robust order intake into 2026, expansion into the Swedish B2C market, and new ROMEGA launches in Asia and continued B2B growth in the U.S., underlining a renewed growth trajectory for the nutraceutical segment. On the pharma side, positive findings from the HeROPA psoriasis trial and a glaucoma pilot study have strengthened the scientific case for its marine-based assets, while preclinical preparations continue for a drug candidate targeting brain development in extremely premature infants and Arctic Algae advances an oral fish vaccine platform with fresh public funding.
The company plans to leverage its clinical data in 2026 through scientific publications and conferences to secure partnerships and project-specific financing, especially for pharma programs that will be funded separately from the nutraceutical business. While liquidity remains closely monitored, the board is evaluating additional measures and maintaining active dialogue with financing partners as Arctic Bioscience balances cost discipline with international expansion and pipeline development.
More about Arctic Bioscience AS
Arctic Bioscience is a Norwegian biotech company that develops and commercializes pharmaceutical and nutraceutical products based on bioactive marine compounds. Its pipeline includes HRO350, an oral drug candidate for mild-to-moderate psoriasis, while its ROMEGA-branded nutraceuticals are sold globally as bulk ingredients and finished consumer products.
Average Trading Volume: 17,393
Current Market Cap: NOK92.46M
For detailed information about 9TD stock, go to TipRanks’ Stock Analysis page.